ImmunoPrecise Antibodies Ltd. (IPA)
| Market Cap | 49.35M |
| Revenue (ttm) | 16.41M |
| Net Income (ttm) | -15.72M |
| Shares Out | 25.05M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,489 |
| Open | 2.05 |
| Previous Close | 2.07 |
| Day's Range | 1.96 - 2.14 |
| 52-Week Range | 1.70 - 5.90 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+306.09%) |
| Earnings Date | Sep 14, 2023 |
About IPA
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In a... [Read more]
Financial Performance
In 2023, IPA's revenue was 20.67 million, an increase of 6.72% compared to the previous year's 19.36 million. Losses were -26.56 million, 59.0% more than in 2022.
Financial numbers in CAD Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for IPA stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 306.09% from the latest price.
News
ImmunoPrecise Antibodies Announces CFO Transition
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effec...
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced fi...
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced tha...
IPA Announces Board Refreshment
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to annou...
IPA Responds to 13D Filing
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the fo...
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-driven biotherapeutic research and technology, is delighted to extend an invita...
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today...
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, toda...
IPA's Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is excited...
IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”) today introduced a transformative AI-driven rapid therapeutic screening p...
IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology c...
IPA to Present at Jefferies Healthcare Conference 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology co...
ImmunoPrecise's Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology co...
European Patent Office to Grant BioKey's Patent Application for Foundational HYFT® Technology
VICTORIA, British Colombia--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStra...
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
VICTORIA, British Colombia--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology c...
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today...
ImmunoPrecise Antibodies' Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
VICTORIA, British Columbia & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biothera...
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today ...
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced ...
IPA's Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced t...
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced t...
IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technolo...
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a volu...
IPA's Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.
NIAID Confirms IPA's PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutic...